Source comparison
PT-141 HSDD Results Timeline Comparison: Onset, Peak, and Duration Across Dosing Protocols
Absorption Phase 15–60 minutes 15–75 minutes 5–20 minutes Intranasal bypasses first-pass metabolism but is not FDA-approved for HSDD Onset of Noticeable Effect 45 minutes–2 hours 30 minutes–90 minutes 20–45 minutes 'Noticeable' ≠ peak; most patients report sub
This comparison does not assign a generated winner or score.
- Absorption Phase
- 15–60 minutes
- 15–75 minutes
- 5–20 minutes
- Intranasal bypasses first-pass metabolism but is not FDA-approved for HSDD
- Onset of Noticeable Effect
- 45 minutes–2 hours
- 30 minutes–90 minutes
- 20–45 minutes
- 'Noticeable' ≠ peak; most patients report subtle warmth or flushing first
- Peak Clinical Efficacy
- 2–6 hours
- 1.5–5 hours
- 1–3 hours
- Compounded higher doses not FDA-reviewed; safety data incomplete
- Duration of Effect
- 8–12 hours
- 10–14 hours
- 6–10 hours
- Duration extends with higher doses but so does nausea incidence
- Return to Baseline
- 18–24 hours
- 24–36 hours
- 16–20 hours
- Residual melanocortin activity persists beyond subjective awareness
- Common Misalignment
- Dosing at T-45min when peak is T+3hr
- Expecting instant effect like PDE5 inhibitors
- Assuming intranasal = faster clinical response
- Timeline education reduces premature discontinuation by 40% (RECONNECT extension data)